GLP-1 Receptor Agonist Market research report by Delvens focuses on primary sections such as – market segments, market outlook, competitive landscape, and company profiles. The segments provide details in terms of various perspectives such as end-use industry, product or service type, and any other relevant segmentation as per the market’s current scenario which includes various aspects to perform further marketing activity.
The global GLP-1 Receptor Agonist Market size is projected to reach a CAGR of 13.3% from 2023-2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/glp1-receptor-agonist-market
Within the pharmaceutical sector, the GLP-1 receptor agonist market is a fast-expanding and changing subsegment. This market is expanding as a result of rising rates of diabetes and obesity, improvements in medication research, and greater public awareness of the value of disease management. The market is now controlled by a small number of significant competitors, including Novo Nordisk and Eli Lilly, although there is room for disruption from more recent entries with novel oral formulations and drug delivery systems.
The oral GLP-1 receptor agonist market is anticipated to develop at the quickest rate in the upcoming years as the market expands. The category for type 2 diabetes is anticipated to have the biggest market share, while the segment for obesity is anticipated to expand quickly as well. The largest and fastest-growing markets are predicted to be in North America and Asia-Pacific. Overall, the market for GLP-1 receptor agonists offers tremendous opportunities for pharmaceutical firms to create and distribute ground-breaking treatments for diabetes and obesity that will enhance the lives of millions of people worldwide.
The prominent players in GLP-1 Receptor Agonist Market are
· Eli Lilly and Company
· GlaxoSmithKline plc
· Novo Nordisk A/S
· PegBio Co., Ltd.
· AstraZeneca
· Intarcia Therapeutics, Inc.
· Amylin Pharmaceuticals, Inc.
· Sanofi
· Hanmi Pharm. Co., Ltd.
· Pfizer Inc.
· Amgen Inc.
· Innovent Biologics
· Jiangsu Hengrui Medicine Co.
· Sun Pharmaceuticals Industries Ltd.
· 9 Meters Biopharma, Inc. and More
North America to Dominate the Market
· North America dominates the glucagon-like peptide 1 (GLP-1) agonists market due to the rise in healthcare.
· Furthermore, the growing research and development. Furthermore, the occurrence of major key players will further boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the region during the forecast period.
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/glp1-receptor-agonist-market
Recent Developments
In May 2022, The US Food and Drug Administration (FDA granted approval for Eli Lilly and Company’s Mounjaro (tripeptide) injection as an adjunct to diet and exercise to enhance glycemic control in adult patients with type 2 diabetes. A single molecule, Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
In July 2021, AstraZeneca’s Bydureon BCise (exenatide extended-release), the once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years).
Key Findings of GLP-1 Receptor Agonist Market are:
· The Drug type Segment is further fragmented into Exenatide, Liraglutide, Dulaglutide, Semaglutide, and others. Semaglutide is expected to be the fastest-growing segment in the GLP-1 receptor agonist market, driven by its efficacy and once-weekly dosing regimen. Exenatide and liraglutide are also expected to grow steadily, while dulaglutide and others may face some competition from new entrants.
· The Brand Segment is further fragmented into Bydureon, Victoza, Trulicity, Ozempic, and Others. Novo Nordisk's semaglutide is expected to be the fastest-growing brand in the GLP-1 receptor agonist market, as it has shown superior efficacy compared to other drugs in the class. Eli Lilly's tripeptide and Chiasma's oral octreotide also have the potential to disrupt the market, though they are still in clinical trials.
· The Route of Administration Segments is further fragmented into Injectable, Oral Formulations. The oral GLP-1 receptor agonist segment is expected to be the fastest-growing, as it offers greater convenience and ease of use for patients. However, injectable formulations will continue to dominate the market, especially for patients with more severe cases of diabetes and obesity.
· The Application Segment is further fragmented into Type 2 Diabetes, Obesity, and Others. The type 2 diabetes segment is expected to account for the largest share of the GLP-1 receptor agonist market, as diabetes is a major and growing public health concern worldwide. However, the obesity segment is also expected to grow rapidly, as GLP-1 receptor agonists have shown promise in promoting weight loss and improving metabolic health.
Access Full Reports: https://www.delvens.com/report/glp1-receptor-agonist-market
In addition to the market data for GLP-1 Receptor Agonist Market, Delvens offers a client-centric report customized according to the company’s specific demand and requirement.
Frequently Asked Questions
· What are the years considered to study GLP-1 Receptor Agonist Market?
· What is the compound annual growth rate (CAGR) of the GLP-1 Receptor Agonist Market?
· Which region holds the largest market share in GLP-1 Receptor Agonist Market?
· Which is the fastest growing region in GLP-1 Receptor Agonist Market?
· Who are the major players in GLP-1 Receptor Agonist Market?
More Reports From Delvens:
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
